Is the intracellular ATP concentration of CD4+ T-Cells a predictive biomarker of immune status in stable transplant recipients?

Transplantation

Volumn 88, Issue SUPPL. 3, 2009, Pages

  Millán, Olga ^a,b   Sánchez Fueyo, Alberto ^a,b   Rimola, Antoni ^a,b   Guillen, David ^a   Hidalgo, Susana ^a   Benitez, Carlos ^a   Campistol, Josep M ^a   Brunet, Merce ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomarker; Immunosuppression; Solid organ transplant.

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; REFERENCE VALUES; SIROLIMUS; SURVIVAL RATE; SURVIVORS; TRANSPLANTATION IMMUNOLOGY;

EID: 70349126317     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181afeba6     Document Type: Article

References (18)

1. Barten MJ, van Gelder T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: New mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002; 2: 719.
2. Millán O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and my-cophenolate mofetil. Clin Chem 2003; 49: 1891.
3. Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8- T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004; 77: 1815.
4. Brunet M, Campistol JM, Diekmann F, et al. T-cell function monitoring in stable renal transplant patients treated with sirolimus mono-therapy. Mol Diagn Ther 2007; 11: 247.
5. Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007; 40: 50.
6. Buttgereit F, Burmester GR, Brand M. Bioenergetics of immune functions: Fundamental and therapeutic aspects. Immunol Today 2000; 21: 192.
7. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 82: 663.
8. Cadillo-Chávez R, Echegaray S, Santiago-Delpín EA, et al. Assessing the risk of infection and rejection in hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transp Proc 2006; 38: 918.
9. Brunet M, Cirera I, Martorell J, et al. Sequential determination of phar-macokinetics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006; 81: 541.
10. Westley IS, Sallustio BC, Morris RG. Validation of a high-perfomance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem 2005; 38: 824.
11. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000; 13(suppl 1): S301.
12. Kirk AD, Mannon RB, Swanson SJ, et al. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2.
13. Mendler M, Kwok H, Franco E, et al. Monitoring peripheral blood CD4- adenosine triphosphate activity in a liver transplant cohort: Insight into the interplay between hepatistis C virus infection and cellular immunity. Liver Transpl 2008; 14: 1313.
14. Gautam A, Fisher SA, Yango AF, et al. Cell mediated immunity (CMI) and post transplant viral infections-role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 2006; 6: 2023.
15. Sanchez-Velasco P, Rodrigo E, Valero R, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transpl 2008; 22: 55.
16. Pons JA, Yelamos J, Ramirez P, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003; 75: 1045.
17. Takatsuki M, Uemoto S, Inomat Y, et al. Weaning of immunosuppres-sion in living donor liver transplant recipients. Transplantation 2001; 72: 449.
18. Israeli M, Yussim A, Mor E, et al. Preceeding the rejection: In search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 2007; 18: 7.